We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
+15.6%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$8.4B
AUM Growth
+$1.66B
Cap. Flow
+$1.33B
Cap. Flow %
15.85%
Top 10 Hldgs %
61.33%
Holding
510
New
182
Increased
113
Reduced
52
Closed
146

Top Buys

Rank Stock Value
1
AGIO icon
Agios Pharmaceuticals
AGIO
+$79.7M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$74.4M
3
KVUE icon
Kenvue
KVUE
+$65.3M
4
ELF icon
e.l.f. Beauty
ELF
+$51.7M
5
GSK icon
GSK
GSK
+$46.6M

Top Sells

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$96.3M
2
EXAS
Exact Sciences
EXAS
+$56.4M
3
PTCT icon
PTC Therapeutics
PTCT
+$34.5M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$28M
5
MDB icon
MongoDB
MDB
+$23M

Sector Composition

Rank Sector Weight
1 Healthcare 32.56%
2 Technology 5.44%
3 Consumer Discretionary 5.13%
4 Consumer Staples 2.69%
5 Communication Services 1.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASO icon
376
Academy Sports + Outdoors
ASO
$2.97B
– –
-10,923
Closed -$546K
ASNS
377
DELISTED
ACTELIS NETWORKS INC
ASNS
– –
-90,160
Closed -$333K
AVTR icon
378
Avantor
AVTR
$9.12B
– –
-25,360
Closed -$316K
BDX icon
379
Becton Dickinson
BDX
$48.5B
– –
-5,010
Closed -$938K
BHVN icon
380
CALL
Biohaven
BHVN
$2.2B
– –
-250,000
Closed -$3.75M
BIRK icon
381
Birkenstock
BIRK
$7.09B
– –
-15,012
Closed -$679K
BPOP icon
382
Popular Inc
BPOP
$11.2B
– –
-2,096
Closed -$266K
BRKR icon
383
Bruker
BRKR
$8.07B
– –
-9,893
Closed -$321K
BROS icon
384
Dutch Bros
BROS
$9.4B
– –
-6,877
Closed -$360K
C icon
385
Citigroup
C
$226B
– –
-8,091
Closed -$821K
CAVA icon
386
CAVA Group
CAVA
$7.39B
– –
-9,966
Closed -$602K
CB icon
387
Chubb
CB
$135B
– –
-857
Closed -$242K
CCI icon
388
Crown Castle
CCI
$32.4B
– –
-3,022
Closed -$292K
CCL icon
389
Carnival Corporation Ltd
CCL
$39.3B
– –
-156,981
Closed -$4.54M
CEG icon
390
Constellation Energy
CEG
$95.9B
– –
-866
Closed -$285K
CHDN icon
391
Churchill Downs
CHDN
$6.04B
– –
-93,429
Closed -$9.06M
CHH icon
392
Choice Hotels
CHH
$4.81B
– –
-2,745
Closed -$293K
CHWY icon
393
Chewy
CHWY
$9.76B
– –
-31,011
Closed -$1.25M
CLX icon
394
Clorox
CLX
$12.8B
– –
-16,923
Closed -$2.09M
CNK icon
395
Cinemark Holdings
CNK
$4.28B
– –
-32,549
Closed -$912K
COLD icon
396
Americold
COLD
$4.17B
– –
-11,427
Closed -$140K
CRL icon
397
Charles River Laboratories
CRL
$12.5B
– –
-1,932
Closed -$302K
CTVA icon
398
Corteva
CTVA
$51.4B
– –
-3,760
Closed -$254K
CVNA icon
399
Carvana
CVNA
$78.5B
– –
-35,550
Closed -$2.68M
DB icon
400
Deutsche Bank
DB
$71.3B
– –
-9,677
Closed -$343K
14 15
16
17 18

Similar funds

CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
RMDI
R.M. Davis Inc Portland, Maine $5.63B AUM 21.26% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $5.57B AUM 23.85% 1-Year Est. Return
O
Ossiam Paris, France $5.69B AUM 30.95% 1-Year Est. Return
DSC
Donald Smith & Co New York $5.56B AUM 47.13% 1-Year Est. Return
ACM
Altimeter Capital Management Boston, Massachusetts $5.7B AUM 36.74% 1-Year Est. Return
PI
PGGM Investments Zeist, Netherlands $5.7B AUM 17.05% 1-Year Est. Return

Armistice Capital's Q4 2025 Portfolio in Review

As of Q4 2025, Armistice Capital held 510 positions worth $8.4B, up 25% from $6.74B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Armistice Capital deployed $1.33B of net new capital in Q4 2025, opening 182 new positions and adding to 113 existing holdings. Its largest new stake was Kenvue: 3,992,196 shares worth $68.9M.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, up from 32% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Travere Therapeutics, an estimated $96.3M trimmed.

  • Armistice Capital's largest Q4 2025 buy was Kenvue: 3,992,196 shares worth $68.9M.
  • Armistice Capital added most to Agios Pharmaceuticals in Q4 2025, an estimated $79.7M increase.
  • Armistice Capital's biggest Q4 2025 reduction was Travere Therapeutics, cutting an estimated $96.3M.
  • Armistice Capital fully exited Exact Sciences in Q4 2025, selling an estimated $56.4M.
  • Armistice Capital's ten largest holdings make up 61% of its $8.4B portfolio in Q4 2025.
  • Armistice Capital opened 182 new positions and closed 146 in Q4 2025.
  • Armistice Capital's portfolio value rose 25% quarter-over-quarter to $8.4B.

Based on Armistice Capital's 13F filing for Q4 2025, filed 17 Feb 2026.